Arcturus Therapeutics

Arcturus Therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics

/wp-content/themes/rewalk-parent/default_media/arcturus_space_1mbit_vbr2.mp4
News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
June 1, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 3, 2013
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego
READ MORE
June 3, 2013
RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round
READ MORE
June 3, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech
READ MORE
January 24, 2022
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
READ MORE
January 25, 2022
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
READ MORE
February 8, 2022
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
READ MORE
February 16, 2022
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
READ MORE
February 28, 2022
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
READ MORE
March 25, 2022
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
READ MORE
April 20, 2022
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
READ MORE
April 27, 2022
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
READ MORE
May 5, 2022
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
READ MORE
May 9, 2022
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
READ MORE
August 1, 2022
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
READ MORE
August 9, 2022
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
READ MORE
August 18, 2022
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
READ MORE
August 31, 2022
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
READ MORE
September 1, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
READ MORE
September 27, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
READ MORE
October 26, 2022
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
READ MORE
November 1, 2022
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
READ MORE
November 8, 2022
Arcturus Therapeutics to Present at the Following Investor Conferences in November
READ MORE
November 9, 2022
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
READ MORE
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/11/Arcturus_Lobby_Large.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/11/Arcturus_Lobby_Small.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2022/07/22ArctP750_crop-scaled.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2022/07/22ArctP750_crop-scaled.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2018/05/18arct1244fxF.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2018/05/18arct1244fxF_230.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/11/ArcBuilding_Final.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/11/building_external_thumbnail.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2018/05/18arct1055fxF.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2018/05/18arct1055fxF_230.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2016/05/main-visual-office-exterior.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/11/main_office_exterior_thumbnail.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2016/05/main-visual-office-interior-tag-line.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/11/building_tagline_thumbnail.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/09/20arctlab286fxFNLLo-scaled.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/11/20arctlab286fxFNLLo_thumbnail.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/09/20arctlab206fxFNLLo-scaled.jpg?time=1669765209
https://e3283a.p3cdn1.secureserver.net/wp-content/uploads/2020/11/20arctlab206fxFNLLo_thumbnail.jpg?time=1669765209

LUNAR®-mediated delivery of RNA into cells

LUNAR® particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR® formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR®components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.